Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK and safety of IV axatilimab in healthy Japanese males
jRCT2071220109Phase 1Completed
- Sponsor
- Incyte
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of axatilimab in graft-versus-host disease (GVHD) (4 cohorts), sponsored by Incyte. Primary endpoint: Number of participants with adverse events. Started Mar 2023; status: completed.
02
Drugs
axatilimab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on jRCT2071220109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220109.